Experimental gene therapy of chronic pain

Current Opinion in Anaesthesiology

Volumn 16, Issue 5, 2003, Pages 547-551

  Pohl, Michel ^a   Meunier, Alice ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Gene therapy of chronic pain; Opioid peptides; Targeted transfer of nucleic acids; Virus derived vectors

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 2; NALOXONE; NEUROTROPHIC FACTOR; NEUROTROPIN; OPIATE PEPTIDE; PROENKEPHALIN; PROTEIN; VIRUS VECTOR;

CHRONIC PAIN; CLINICAL PROTOCOL; DNA SEQUENCE; DNA TRANSFER; DRUG EFFECT; EXPERIMENTATION; GENE GUN; GENE OVEREXPRESSION; GENE THERAPY; IN VIVO STUDY; NERVE INJURY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW; SCIATIC NERVE; SENSITIZATION;

EID: 0142124864     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200310000-00017     Document Type: Review

References (40)

1. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1998; 57:1-164.
2. Wang H, Sun H, Della K, et al. Chronic neuropathic pain is accompanied by global changes in gene expression and shares pathobiology with neurodegenerative diseases. Neuroscience 2002; 114:529-546. This interesting study documented the complexity of the modulation of gene expression occurring after induction of neuropathic pain in rat.
3. Pohl M, Braz J. Gene therapy of pain: emerging strategies and future directions. Eur J Pharmacol 2001; 429:39-48.
4. Wu CL, Garry MG, Zollo RA, Yang J. Gene therapy for the management of pain Part II. Anesthesiology 2001; 95:216-240.
5. Antunes Bras JM, Epstein AL, Bourgoin S, et al. Herpes simplex virus-1 mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem 1998; 70:1299-1303.
6. Finegold AA, Mannes AJ, Iadarola MI. A paracrine paradigm for in vivo gene therapy in the central nervous system: Treatment of chronic pain. Hum Gene Ther 1999; 10:1251-1257.
7. Lebedeva I, Stein CA. Antisense oligonucleotides: promise and reality. Annu Rev Pharmacol Toxicol 2001; 41:403-419.
8. Hannon GJ. RNA interference. Nature 2002; 418:244-251. An excellent and accessible overview of biological functions of RNA interference, and the interest for this powerful tool in genomics.
9. Burton EA, Wechuck JB, Wendel SK, et al. Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells 2001; 19:358-377.
10. Lilley CE, Branston RH, Coffin RS. Herpes simplex virus vectors for the nervous system. Curr Gene Ther 2001; 1:339-358.
11. Lowenstein PR, Castro MG. Genetic engineering within the adult brain: implications for molecular approaches to behavioral neuroscience. Physiol Behav 2001; 73:833-839.
12. Hsich G, Sena-Esteves M, Breakefield XO. Critical issues in gene therapy for neurologic disease. Hum Gene Ther 2002; 13:579-604. This is one of the rare reviews in this domain, giving a sufficiently emphasized view on the possible therapeutic interest of gene-based intervention in the central nervous system.
13. Wilson SP, Yeomans DC, Bender MA, et al. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA 1999; 96:3211-3216.
14. Braz J, Beaufour C, Coutaux A, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 2001; 21:7881-7888.
15. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50:355-363.
16. Hao S, Mata M, Goins W, et al. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain 2003; 102:135-142. This interesting study provided some evidence of differential biological effects of morphine or locally overproduced endogenous opioid from viral-derived vectors.
17. Goss JR, Harley CF, Mata M, et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol 2002; 52:662-665.
18. Lu CY, Chou AK, Wu CL, et al. Gene-gun particle with pro- opiomelanocortin cDNA produces analgesia against formalin-induced pain in rats. Gen Ther 2002; 9:1008-1014.
19. Lin CR, Yang LC, Lee TH, et al. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther 2002; 9:1247-1253.
20. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33:87-107.
21. 2-mediated inhibition. Nature 2001; 411:957-962.
22. Cejas PJ, Martinez M, Karmally S, McKillop M. Lumbar transplant of neurons genetically modified to secrete brain-derived neurotrophic factor attenuate allodynia and hyperalgesia after sciatic nerve constriction. Pain 2000; 86:195-210.
23. Boucher TJ, Okuse K, Bennet DL, et al. Potent analgesic effects of GDNF in neuropathic pain states. Science 2000; 290:124-127.
24. Airaksinen MA, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002; 3:383-394. This very useful review provides an excellent insight into glial-derived neurotrophic factor biology.
25. Kirstein M, Farinas I. Sensing life: regulation of sensory neuron survival by neurotrophins. Cell Mol Life Sci 2002; 59:1787-1802. This excellent review focuses on recent data issued from gene deletion experiments in mouse in relation with the primary sensory system.
26. Eaton MJ, But B, Ruitenberg MJ, et al. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther 2002; 9:1387-1395. In this interesting study the authors demonstrated both antiallodynic and antihyperalgesic potency of sustained, viral vector-mediated, spinal production of BDNF in rat with CCI-induced neuropathic pain.
27. Poole S, de Queiraz Cunha F, Ferreira SH. Hyperalgesia from subcutaneous cytokines. In: Watkins LR, Maier SF, editors. Cytokines and pain. Basel: Birkhäuser Verlag; 1999. pp. 59-87.
28. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci 2001; 24:450-455.
29. Milligan ED, Twining C, Chacur M, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003; 23:1026-1040.
30. Raghavendra V, Rutkovski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 2002; 22:9980-9989. This elegant study provided clear evidence that control of central glial activation and proinflammatory cytokine overproduction at the spinal level may improve the opioid therapy of chronic neuropathic pain.
31. Machelska H, Stein C. Immune mechanisms in pain control. Anesth Analg 2002; 95:1002-1008. This is an excellent introduction to the broad domain of immune and pain mechanism interactions at the peripheral level.
32. Song P, Zhao ZQ, Liu XY. Expression of IL-2 receptors in dorsal root ganglia neurons and peripheral antinociception. Neuroreport 2000; 11:1433-1436.
33. Song P, Zhao ZQ. Interleukin 2-induced antinociception partially coupled with mu receptor. Cytokine 2000; 12:1240-1242.
34. Yao MZ, Gu JF, Wang JH, et al. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience 2002; 112:409-416.
35. Marshall JS, Leal-Berumen I, Nielsen L, et al. Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. J Clin Invest 1996; 97:1122-1128.
36. Poole S, Cunha FQ, Selkirk S, et al. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br J Pharmacol 1995; 115:684-688.
37. Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain 1998; 74:35-42.
38. th World Congress on Pain; August 17-22; San Diego. Seattle: IASP press; 2002. p. 135.
39. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413:203-210.
40. Hoogerwerf WA, Zou L, Shenoy M, et al. The proteinase-activated receptor 2 is involved in nociception. J Neurosci 2001; 21:9036-9042.